Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 848: Nivolumab +/- Ipilimumab in TMB-H Solid Tumors
NCT03668119Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2018
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 2 trial of nivolumab in solid tumor, sponsored by Bristol Myers Squibb. Started Oct 2018; status: completed.
02
Drugs
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03668119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03668119.